chromatin immunoprecipitation assays have contributed greatly to our understanding of the role of histone modifications in gene regulation. however, they do not permit analysis with single-cell resolution, thus confounding analyses of heterogeneous cell populations. here we present a method that permits visualization of histone modifications of single genomic loci with single-cell resolution in formaldehyde-fixed paraffin-embedded tissue sections based on combined use of in situ hybridization and proximity ligation assays. We show that dimethylation of lysine 4 of histone h3 (h3K4me2) at the MYH11 locus is restricted to the smooth muscle cell (smc) lineage in human and mouse tissue sections and that the mark persists even in phenotypically modulated smc in atherosclerotic lesions that show no detectable expression of smc marker genes. this methodology has promise for broad applications in the study of epigenetic mechanisms in complex multicellular tissues in development and disease.
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Epigenetics is defined as a heritable code other than the genomic sequence and includes histone post-translational modifications, DNA methylation and ATP-dependent chromatin remodeling [1] [2] [3] . Differentiation from embryonic stem cells (ESCs) to multiple differentiated cell types requires that the spatiotemporal expression of gene patterns be established 4, 5 . As one example out of many [6] [7] [8] [9] , we have previously shown that an SMC-specific epigenetic repertoire of histone modifications are acquired during development of SMC from ESC, including H3K4me2 at SMC marker genes such as ACTA2 and MYH11, the latter being the most specific marker of SMC lineage [10] [11] [12] . Notably, results show that H3K4me2 of these genes is restricted to SMCs and is absent in non-SMCs. Moreover, H3K4me2 enrichment of these genes persists when cultured SMCs are induced to undergo phenotypic switching to a less differentiated state 11 , a process dependent on activation of the ESC pluripotency factor KLF4 both in vivo 13 and in cultured cells 11 . These results suggest that H3K4me2 of the MYH11 and other SMC marker gene loci represent stable epigenetic markers of SMC lineage. However, a major limitation in studies thus far is that data are derived nearly exclusively from studies in cultured SMCs, which are poorly differentiated because cell culture systems do not recapitulate complex environmental cues that detection of histone modifications at specific gene loci in single cells in histological sections Delphine Gomez 1,2 , Laura S Shankman 1,2 , Anh T Nguyen 1 & Gary K Owens 1 regulate SMC differentiation in vivo 14, 15 under normal as well as pathological conditions. Moreover, it is impossible to obtain chromatin derived exclusively from SMCs from tissue sources because all SMC-containing tissues contain multiple other cell types. Conversely, all non-SMC tissues contain large numbers of SMCs because all tissues are vascularized. As such, conventional chromatin immunoprecipitation (ChIP) 16, 17 analyses cannot be used to rigorously test whether H3K4me2 of SMC gene loci are an exclusive epigenetic signature of SMC lineage in vivo. Indeed, an important general limitation of ChIP assays is that they do not permit analysis of histone modifications at a given gene locus in individual cells, thus confounding interpretation of analyses of heterogeneous cell populations and precluding direct assessment of the role of specific histone modifications within individual cell types in complex multicellular tissues, including disease specimens. For example, ChIP analyses on a tumor biopsy or atherosclerotic tissue specimen represent a composite signal derived from the many different cell types present in that tissue sample. Although one may perform ChIP assays on a given cell population obtained by cell sorting, such analyses result in the loss of critical information regarding the spatial orientation of cells within tissues and may be subject to epigenetic changes that occur during the tissue dissociation and/or sorting procedures.
Here we describe a method that permits visualization of histone modifications at a single genomic locus in human and mouse formalin-fixed paraffin-embedded tissue sections that is the equivalent of a single-cell ChIP assay, combining in situ hybridization (ISH) and proximity ligation assay (PLA) methods. We demonstrate that H3K4me2 of the MYH11 gene locus is a highly specific marker of SMC lineage in vivo that persists even in phenotypically modulated SMCs in atherosclerotic lesions that lack detectable expression of endogenous SMC marker genes.
results
Our overall strategy made use of the PLA [18] [19] [20] to detect proximity between a biotin-labeled probe targeting the MYH11 promoter and H3K4me2 at this locus ( Fig. 1a) . PLA is widely performed for detection of protein-protein interaction or protein post-translational modifications in both cultured cells and tissue sections 20, 21 , but it has not, to our knowledge, been used for assessing histone modifications at specific gene loci. We sought to combine PLA with ISH methods using two primary antibodies targeting (i) histone modifications and (ii) biotin residues included in a probe annealing to the genomic locus of interest. We first assessed the feasibility of the approach by estimating intermolecular distances between DNA and histone tails to ascertain the compatibility with the PLA range of detection of approximately 40 nm ( Supplementary Fig. 1 ). The major methodological steps included (i) immunostaining of human or mouse formalin-fixed paraffin-embedded tissue sections with antibodies to SMC or non-SMC markers, (ii) ISH with a biotinylated DNA probe targeting the MYH11 locus and (iii) a PLA including incubation with anti-biotin (rabbit) and H3K4me2 (mouse) primary antibodies. We verified that nuclear detection of H3K4me2 was preserved after the ISH procedure ( Supplementary Fig. 2 ) and mapped H3K4me2 enrichment of the MYH11 promoter to identify boundaries for our ISH probe ( Supplementary  Fig. 3 ). Moreover, for validation of our ISH procedure, we used a 5-TAMRA-dUTP-labeled Y chromosome probe in human samples from male patients, and we observed similar hybridization efficiencies of the Y chromosome in SMCs and non-SMCs cell types ( Supplementary Fig. 4) .
We performed ISH-PLA detection of H3K4me2 at the MYH11 locus in human coronary arteries because these are highly relevant to atherosclerotic disease. These vessels contain three distinct cell layers: the intima, consisting of endothelial cells (ECs); the media, composed primarily of smooth muscle α-actin + (ACTA2 + ) SMCs; and the adventitia, composed mainly of fibroblasts negative for SMC markers but with abundant small blood vessels (Fig. 1b) . We initially focused on small arteries within the adventitia of coronary arteries, which have a well-defined SMC layer. MYH11 H3K4me2 PLA + signal (visualized by red spots in the nucleus) was observed exclusively npg within ACTA2 + medial SMCs (Fig. 1c) , whereas adventitial cells and ECs (CD31 + ) were PLA − . We used an empty biotinylated vector as a negative control, and it showed no PLA amplification in SMCs and non-SMCs, demonstrating that the MYH11 probe was required for PLA amplification (Fig. 1d) . To further validate our ISH-PLA method, we compared results of ISH-PLA and ChIP assays in cultured cells ( Fig. 1e-g and Supplementary Fig. 5 ). These results showed complete concordance in that H3K4me2 enrichment of the MYH11 locus was observed exclusively in SMCs by both ChIP and ISH-PLA analyses. To provide a model system for testing the stability of the MYH11 H3K4me2 mark in phenotypically modulated SMCs in vivo, we developed an SMC lineage-tracing system by crossing Myh11-CreER T2 mice 22 with ROSA26 STOP-flox EYFP +/+ mice (SMC-EYFP +/+ mice) ( Supplementary Fig. 6a ). Tamoxifen treatment of mice from ages 6 to 8 weeks, to induce Cre-mediated recombination, resulted in high-efficiency EYFP expression exclusively in SMCs in all tissues examined ( Fig. 2a-c and Supplementary Fig. 6 ). In contrast, no detectable expression of EYFP was observed without tamoxifen treatment ( Fig. 2a ) or in SMC-EYFP −/− mice treated with tamoxifen ( Fig. 2c ), whereas >95% of medial cells within SMC-EYPF +/+ mice were EYFP + (Fig. 2d) , indicating high efficacy of SMC-specific recombination. Moreover, a substantial fraction of EYFP + SMCs in large arteries (such as the aorta) of these SMC-EYFP +/+ mice were Myh11 H3K4me2 PLA + (Fig. 2d) . In contrast, non-SMCs including ECs were Myh11 H3K4me2 PLA − . We saw no PLA signal in negative controls using an empty cloning vector as a probe in place of the MYH11 in situ probe ( Fig. 2e) . We estimated that ISH-PLA has an equivalent efficiency (66%) to that of regular FISH procedures (64%) ( Supplementary Figs. 4 and 7) . Moreover, we found comparable efficiency using human and mouse tissue sections.
To test whether ISH-PLA could be readily adapted to examination of additional gene loci or histone modifications, we performed ISH-PLA experiments using a probe targeting the vascular endothelial-cadherin promoter (CDH5). CDH5 is a specific marker of the EC lineage 23 , and enrichment of H3K4me2 is found on this promoter specifically in cultured ECs as determined by conventional ChIP assays 11 . Results of analyses of mouse and human tissue sections of healthy vessels showed specific CDH5 H3K4me2 PLA + staining of ECs. In contrast, SMCs (medial ACTA2 + in human and EYFP + in SMC-EYFP +/+ mouse) were strictly PLA − (Supplementary Fig. 8 ). We also performed PLA analysis of H4 acetylation of SM22α (Tagln), a gene selectively expressed in SMCs in healthy adult blood vessels 24, 25 . Consistent with expectations, Tagln H4 acetylation PLA + staining was restricted to SMCs (Supplementary Fig. 9 ).
Multiple non-SMCs including ECs, fibroblasts and ESCs in culture show marked enrichment of histone H3 Lys27 trimethylation (H3K27me3) at the MYH11 gene locus as determined by ChIP assays, consistent with its transcriptional silencing in these cells 11 . Thus, to further validate our PLA method in vivo, we evaluated not only H3K4me2 but also H3K27me3 at the MYH11 locus in human carotid arteries ( Fig. 3a) . Consistent with PLA results in small arteries in the adventitia (Fig. 1c) and ChIP results in cultured cells ( Supplementary Fig. 5 ), MYH11 H3K4me2 PLA + cells were restricted to ACTA2 + SMCs in the media, whereas adventitial fibroblasts and endothelial cells were negative ( Fig. 3b and Supplementary Fig. 10 ). We did not observe any PLA amplification when we used an irrelevant probe ( Fig. 3c) . Medial SMCs were negative for H3K27me3 of the MYH11 locus, whereas ECs (CD31 + cells) ( Fig. 3d ) and adventitial fibroblasts (ACTA2 − cells) (data not shown) were positive for this silencing mark on the basis of PLA analyses. Consistent with these results in human coronary arteries, PLA analyses of human brain sections ( Fig. 3e and Supplementary Fig. 11 ) showed exclusive MYH11 H3K4me2 PLA labeling of SMCs, whereas neuronal cells were MYH11 H3K4me2 PLA − but MYH11 H3K27me3 PLA + . These results suggest that our ISH-PLA method can reliably and specifically detect histone modifications at specific gene loci in single cells in human and mouse tissue sections, and they are consistent with results of our previous studies using conventional ChIP assays on npg cultured cells 11 . However, the studies here are, to our knowledge, the first to identify a cell type-and locus-specific histone modification in cells in vivo within intact tissue sections in a complex multicellular tissue specimen. Furthermore, we provide evidence that H3K4me2 of the MYH11 gene locus represents a unique and specific epigenetic signature of cells of the SMC lineage in vivo.
Finally, we show that our PLA methodology is readily adaptable to multiple gene loci and histone modifications. Mature SMCs retain remarkable plasticity and can undergo phenotypic switching characterized by markedly decreased SMC marker gene expression and increased proliferation and migration under pathological conditions such as atherosclerosis 14, 26, 27 . However, because phenotypically modulated SMCs downregulate expression of SMC markers (including ACTA2 and MYH11), there are major ambiguities as to which cells within lesions are derived from SMCs 28 . Previous studies demonstrated that PDGF-BB-induced phenotypic switching of cultured SMCs was associated with marked reductions in SMC marker expression and reduced H4 acetylation but no changes in H3K4me2 enrichment of the ACTA2 or MYH11 promoters 11 . We extended these studies herein by showing that induction of SMC phenotypic switching with the pro-atherogenic oxidized phospholipid POVPC had similar effects, including reduced MYH11 expression but no change in MYH11 H3K4me2 enrichment (Fig. 4a,b) .
To determine whether Myh11 H3K4me2 persists during SMC phenotypic switching in vivo, we generated advanced atherosclerotic lesions by crossing our SMC-EYFP +/+ mice with ApoE −/− mice and feeding them a Western diet for 18 weeks (Online Methods). We identified large numbers of phenotypically modulated SMCs in lesions that showed no detectible expression of MYH11 (Fig. 4c) or ACTA2 ( Fig. 4d) and were identifiable as being of SMC origin only through detection of the SMCspecific EYFP lineage-tracing gene product. In contrast, the majority of medial SMCs were ACTA2 + (Fig. 4d,e) . Notably, our SMC npg lineage-tracing model is conditionally activated through an ER T2 -Cre system, allowing us to permanently lineage-tag mature SMCs that were expressing MYH11 during the tamoxifen treatment period (6-8 weeks of age). These cells and their progeny constitutively express EYFP, allowing us to lineage-trace these cells independently of the expression of traditional SMC markers, which can be downregulated. In contrast, any SMC derived from a non-SMC source at a later time point will not express EYFP. Results of our studies with this highly rigorous SMC lineage-tracing system showed that >95% of SMC-derived cells in atherosclerotic lesions in brachiocephalic arteries of SMC-EYFP +/+ ApoE −/− mice were not detectable as being of SMC origin via ACTA2 (Fig. 4d,f) or MYH11 immunostaining (Fig. 4c) . Moreover, we showed that the majority of these cells were Myh11 H3K4me2 PLA + (Fig. 4f) .
Taken together, the preceding results not only establish the SMC specificity of H3K4me2 of the MYH11 gene locus but also show that this epigenetic mark is stable in vivo even in SMCs that are not identifiable as being of SMC origin by detection of endogenous marker genes. Furthermore, our results indicate that one may use detection of MYH11 H3K4me2 by ISH-PLA as an epigenetic lineage-tracing system for assessing the role of SMC in the pathogenesis of several major human diseases in which SMC phenotypic switching is postulated to play an important role, including atherosclerosis, cancer, asthma and hypertension. Indeed, consistent with this possibility, we found that a large fraction of cells in advanced atherosclerotic lesions in human coronary arteries did not express SMC marker genes such as ACTA2 and MYH11 ( Fig. 5a and Supplementary Fig. 12 ) but were MYH11 H3K4me2 PLA + (Fig. 5b) . In addition, we detected MYH11 H3K27me3 PLA + cells in only ACTA2 − cells in the lesions, not in medial ACTA2 + SMCs (Fig. 5c) . In contrast, MYH11 H4 acetylation was restricted to medial ACTA2 + SMCs and was absent in lesion cells (Supplementary Fig. 13 ).
We present a summary model of histone modifications in differentiated mature SMCs versus phenotypically modulated SMCs on the basis of observations in vivo in the present studies and our previous studies in cultured SMCs 11 (Fig. 5d) .
discussion
Although several groups 29, 30 have used PLA to detect proteinnucleic acid interactions in vitro, our studies are the first, to our knowledge, to describe a method that permits detection of specific histone modifications at a given gene locus in single cells in fixed histological specimens. We believe this technique will have tremendous utility for investigating the role of epigenetic changes in development and disease. Indeed, there is a large body of research studies that have investigated the role of epigenetic regulation and chromatin signatures during stem cell differentiation or development of specific types of cancer 31 . Nevertheless, the technical limitations of ChIP assays do not allow the in vivo characterization of such epigenetic signatures except in the study of hematopoietic stem cells 32 or leukemia 33 , in which cell sorting can be performed without extensive tissue dissociation before ChIP analyses. Thus, we believe that ISH-PLA will be a powerful tool for the investigation of epigenetic regulation in solid tumors, in which it is virtually impossible to ascertain whether a given epigenetic change is present within tumor or stromal cells. Similarly, our ISH-PLA method will have utility in investigating the role of specific histone modifications at selective gene loci of complex multicellular tissues during development. Moreover, the method's applicability to paraformaldehyde-fixed paraffin-embedded tissue specimens, the standard protocol for archiving human biopsy specimens, will allow unprecedented studies of the role of epigenetic changes in the pathogenesis of human diseases using existing tissue banks. Finally, we believe that our ISH-PLA method may be adapted for the detection and visualization of DNA methylation or transcription factor binding on specific promoters with single-cell resolution, which will further expand our ability to investigate Our results show persistence of a cell-specific epigenetic signature when cells undergo phenotypic transitions to a less differentiated or altered phenotypic state in vivo, wherein the cell origin cannot be identified by detection of endogenous cellselective marker genes. Evidence of appearance and maintenance of cell-specific epigenetic signature (other than the SMC lineage) have been previously described but with the limitation that results were based on studies in cultured cells under conditions that fail to recapitulate complex cell-cell, cell-matrix and other critical environmental cues that exist in vivo 34, 35 . In addition to having important implications for lineage tracing of cells in complex tissues, including human biopsy specimens, these observations may also have critical implications for the propagation of epigenetic mechanisms that control cell-lineage memory and cell-specific bookmarking during cell mitosis, normal development and disease progression 34, 36 . However, it remains to be determined whether persistence of H3K4me2 of SMC gene loci is important in the ability of SMCs to undergo reversible phenotypic switching during repair of vascular injury. That is, our studies have provided no evidence as to whether this histone modification plays a causal role in controlling SMC lineage and phenotype. Further mechanistic studies are needed in this important area but at present are not possible because of the lack of an approach to selectively remove this mark exclusively at SMC gene loci.
Our results indicate that numerous studies of atherosclerosis that relied on identification of intimal SMC as determined by detection of ACTA2 have grossly underestimated the frequency of SMCs within lesions and likely failed to detect possible transition of these cells to alternative phenotypes that may be critical in the pathogenesis of the disease. Until now, lineage tracing of lesion cells in vivo in human studies has been restricted to studying the possible role of hematopoietic cells in lesions on the basis of analyses of cross-gender bone marrow transplant specimens combined with Y chromosome detection by in situ hybridization 37 . However, these approaches are highly limited because such samples are extremely rare, the approach does not allow rigorous npg lineage tracing of nonhematopoietic cells, and results are confounded by development of transplant atherosclerosis, which has a different etiology than normal atherosclerosis. We believe that ISH-PLA will greatly advance studies of human atherosclerosis by facilitating novel studies of the mechanisms and factors that regulate phenotypic transitions in SMCs in atherosclerotic lesions and their possible functional roles in plaque development, progression and end-stage events leading to clinical complications such as myocardial infarction or stroke.
methods
Methods and any associated references are available in the online version of the paper. 37 . Hybridization mixture containing biotinylated probes or 5-TAMRA-dUTP-labeled Y chromosome probe (Clone RP11-88F4, Empire Genomics) was applied on sections. Sections were incubated at 80 °C for 5 min followed by 16-24 h at 37 °C. Hybridization was followed by multiple washes in 2× SSC, 0.1% NP-40 buffer.
Proximity ligation assay. PLA was performed directly after ISH according to the manufacturer's instructions (Olink). After the blocking step, sections were incubated with mouse H3K4me2 (5 µg/mL, clone CMA303, Millipore), mouse H3K27me3 (5 µg/mL, ab6002, Abcam), mouse H4ac (5 µg/mL, clone 3HH4-4C10, Millipore) and rabbit biotin (5 µg/mL, ab53494, Abcam) antibodies overnight at 4 °C, followed by incubation with secondary antibodies conjugated with PLA probe at 37 °C for 1 h as recommended by the manufacturers. Then ligation and amplification were performed (Duolink detection kit Orange, 555 nm). Finally, mounting medium with 4,6-diamidino-2-phenylindole (DAPI) was used.
Image acquisition and analysis. Images were acquired with an Olympus BX41 fitted with a Q imaging Retiga 2000R camera. Image acquisition was performed with the Q Capture Pro software (Media Cybernetics and QImaging). Settings were fixed at the beginning of both acquisition and analysis steps and were unchanged. Brightness and contrast were lightly adjusted after merging. Image analysis was performed with ImageJ. Confocal images were acquired using a Zeiss LSM700 scanning confocal microscope with 405-nm, 488-nm, 555-nm and 637-nm solid-state lasers. Analysis of confocal images was completed using Zeiss Zen 2009 software. nAture methods Chromatin immunoprecipitation. ChIP was performed on cultured cells as previously described 11 . Cells were fixed with 1% paraformaldehyde for 10 min at room temperature. Cross-linking was stopped by addition of 125 mM glycine for 10 min. The cross-linked chromatin was sonicated to shear chromatin into fragments of 200-600 base pairs. The sheared chromatin was immunoprecipitated with 2 µg of H3K4me2 antibody (clone CMA303, Millipore), negative control was incubated with mouse IgG and input DNA without antibody, and immune complexes were recovered with magnetic beads (Millipore).
Quantitative PCR. Total RNA was prepared from cultured cells using Trizol (Invitrogen) according to the manufacturer's protocol. One microgram of RNA was used for reverse transcription with iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed (iQ SYBR Green Supermix, Bio-Rad) on cDNA or DNA extracted after ChIP using primers listed in Supplementary Table 1 .
Statistics. Values are expressed as mean ± s.d. For ChIP, three independent experiments were performed. Each experiment was repeated in triplicate. Comparison between groups was tested using ANOVA. A value of P ≤ 0.05 was considered significant.
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